Earnings Update: Complementary Research on Tantech Holdings, Sypris Solutions, Swisher Hygiene, XTL Biopharmaceuticals, ADMA Biologics

May 18, 2015, 08:40 ET from Analysts Review

NEW YORK, May 18, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom. 

Moments ago, Analysts Review released new research updates concerning several important developing situations including Tantech Holdings Ltd (NASDAQ: TANH), Sypris Solutions Inc. (NASDAQ: SYPR), Swisher Hygiene Inc. (NASDAQ: SWSH), XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB), and ADMA Biologics, Inc. (NASDAQ: ADMA). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.


Today's update concerns the following companies:


Full PDF Download Links (you may have to copy and paste the following links into your browser):

TANH Research Report: ( http://get.analystsreview.com/pdf/?c=Tantech%20Holdings&d=18-May-2015&s=TANH ),

SYPR Research Report: ( http://get.analystsreview.com/pdf/?c=Sypris%20Solutions&d=18-May-2015&s=SYPR ),

SWSH Research Report: ( http://get.analystsreview.com/pdf/?c=Swisher%20Hygiene&d=18-May-2015&s=SWSH ),

XTLB Research Report: ( http://get.analystsreview.com/pdf/?c=XTL%20Biopharmaceuticals&d=18-May-2015&s=XTLB ),

ADMA Research Report: ( http://get.analystsreview.com/pdf/?c=ADMA%20Biologics&d=18-May-2015&s=ADMA ).



Analyst Update: Financial Results for the Quarter

U.S. stocks mostly drifted between modest gains and losses on Friday, May 15, 2015 as investors remained cautious over weaker than expected economic data. The Dow Jones Industrial Average gained 0.11%, to finish at 18,272.56, the S&P 500 rose 0.08%, to 2,122.73, and the NASDAQ Composite ended the day at 5,048.29, down 0.05%. European stocks closed lower on Friday amid rise in the value of euro against dollar. Germany's DAX 30 lost 0.98%, France's CAC 40 fell 0.71%, and London's FTSE 100 closed 0.18% lower on Friday. Meanwhile, Asian markets painted a mixed picture on Friday. The Shanghai Composite fell as expectation of Chinese stimulus measures cooled, while Hong Kong's Hang Seng and Japan's Nikkei gained on Friday.

According to a Bloomberg report, Tantech Holdings released its Full Year 2014 financial results (period ended December 31, 2014) on April 30, 2015. Revenues for the year 2014 increased by 7% YoY to almost $65.5 million. Gross profit increased by 20.3% YoY to $20.6 million in 2014, while gross profit margin improved from 28.0% in 2013 to 31.5% in 2014.

Sypris Solutions, on May 14, 2015, announced financial results for the first quarter 2015 (period ended April 5, 2015). Revenue for the first quarter 2015 was $37.0 million, a decline of 56.1% YoY. By segment, revenue for Sypris Technologies decreased significantly by 63.0% YoY to $28.1 million in Q1 FY 2015, primarily as a result of the cessation of its Dana business which represented approximately 59% of total business

Swisher Hygiene (Swisher), on May 11, 2015, announced financial results for the first quarter 2015. Total revenue for Q1 2015 was $43.8 million, down 9.2% YoY. Total costs and expenses fell by 14.0% YoY to $52.8 million in Q1 2015, primarily due to improved operating efficiencies resulting in headcount reductions. The Company reported a net loss of $8.8 million, or basic and diluted share of $0.50, as compared to a net loss of $13.8 million, or basic and diluted share of $0.78, in Q1 2014.

According to Bloomberg, XTL Biopharmaceuticals (XTL), on April 28, 2015, announced its financial and operational results for the full year ended December 31, 2014. The Company reported a net loss from continuing operations of $2.1 million or basic and diluted share of $0.009 for 2014, compared to a net loss of $1.1 million or basic and diluted share of $0.005 in 2013.

On May 12, 2015, ADMA Biologics announced its financial results for the first quarter 2015. Revenue for Q1 2015 was $1.5 million, lower than $1.6 million reported in the same quarter a year ago. The Company reported a net loss of $3.6 million or $0.37 per share, as compared to a net loss of $5.9 million or $0.64 per share in the first quarter of 2014.


About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.


Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review